
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer ...
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration. Significant tumor reduction was observed in both administration routes. Both IT and IV were well-tolerated and demonstrated enhanced IFN-γ expression in …